Going Woke: An Insider's Look at Corporate America’s "Social Justice Scam"


By Dr. Richard D. Kocur


Coca-Cola, Google, Delta Airlines, Blackrock, Unilever, and Facebook. On its face, this list may sound like a great investment portfolio. Instead, as shown in a new book by former biotech CEO Vivek Ramaswamy, these companies serve as the posterchildren of woke capitalism.


Ramaswamy, author of Woke, Inc.- Inside Corporate America’s Social Justice Scam, uses examples from these companies, and many others, to assert his belief that woke organizations who signal commitments to various social causes do so to scam consumers with “the illusion that by engaging in normal acts of consumption we’re fulfilling our social obligations.” Said another way, consumers are being scammed to believe that supporting the right companies with our money somehow makes the world a better place.


Ramaswamy’s wide-ranging book clearly comes down in support of traditional shareholder capitalism—where the main duty of a company is the commitment to driving value for its shareholders. This is juxtaposed with many of the examples the author provides of stakeholder capitalism—defined by corporations that believe they have a duty to address the societal issues important to their stakeholders, such as climate change and racism. The obvious implication is that anyone could be a stakeholder and thus all issues facing society are issues worthy of corporate attention and support or opposition.


Even without the information presented in Woke, Inc., one can see stakeholder capitalism at play in the corporate actions following the death of George Floyd and the passage of Georgia’s voting law.


In one of the more interesting points in the book, the author links the increasingly woke actions of corporations with an ever-growing political divide; in essence, using companies as proxies to signal political identity. Ramaswamy states, “When corporations take sides in America’s partisan culture war, they’re not just signaling their tribe, they’re selling you an easy way to signal yours.”


The author’s point is exemplified by the tug-of-war over Goya Foods. When Goya Foods’ CEO Robert Unanue lauded President Donald Trump, Goya was immediately subject to boycotts and protests. If one purchased Goya products it signaled support for Trump, whereas conversely if one boycotted Goya, it was a statement in opposition to Trump. This trend is not just dangerous for companies like Goya, but for our democratic process in general. A preference for a particular soft drink, clothing brand, or chicken sandwich should have no bearing on political affiliation or social connections.


Ramaswamy also provides additional background on the rise of woke capitalism by noting the influence of big tech, academia, foreign governments, and what he calls the “new managerial class.” And though these areas are connected to the actions of many of today’s corporations, the author misses an opportunity to delve more deeply into the significant influence of social media, particularly Twitter, when it comes to corporate motivations. In addition, the reader of Woke, Inc. will likely be left wanting when it comes to solutions for stemming the influence of woke corporations. For example, the author’s proposal for protecting the speech rights of employees within a woke corporation are too legalistic and, frankly, unrealistic to consider viable. Lastly, while the actions of woke corporations are apparent and harmful, their true motivation for such actions are not entirely clear. Ramaswamy’s assertion that these corporations are purposefully using woke causes as an opportunity to increase profits at times borders on the conspiratorial.


Nonetheless, Woke, Inc. is an informative and enlightening book on the current state of corporate America and provides good background for those interested in learning more about stakeholder capitalism. Despite some of its shortcomings, it’s a book that can arm consumers with something more valuable than the buying power of any coupon. It provides them with the knowledge to make informed decisions about what, when, why, and from whom they buy.


Dr. Richard D. Kocur is an assistant professor of business at Grove City College. He specializes in marketing and business strategy and has over 25 years of experience in the healthcare industry.

More Resources


11/20/2024
What Donald Trump's Revenge Agenda Is Hiding
Look past the flashy and controversial Cabinet nominees to find that Project 2025 is already being implemented

more info


11/20/2024
Make Education Great Again!
Imagine these words as the first speech delivered by the incoming Secretary of Education.Today, I am here to deliver bitter medicine: American education has failed. Teachers and parents, administrato

more info


11/20/2024
Time-Honored Tradition of Blaming the Left for Dem Defeats
This argument is particularly unconvincing this time around. And it doesn't offer a realistic prescription for future success.

more info


11/20/2024
Dems Are Going To Get Younger and More Radical


more info


11/20/2024
The Blurred Line Between X and the Trump Administration
Forget the ridiculous

more info


11/20/2024
DOGE Is a Great Idea. Trump Should Make It Permanent
DOGE represents a harbinger of deregulation for an incoming Trump administration, especially with Dogecoin enthusiast Elon Musk and Vivek Ramaswamy at the helm.

more info


11/20/2024
The DOGE Plan To Reform Government
Following the Supreme Court's guidance, we'll reverse a decadeslong executive power grab.

more info


11/20/2024
Could Trump Actually Get Rid of the Department of Education?
Getting rid of the agency would cause a lot of harm and wouldn't really change school curriculum.

more info


11/20/2024
How Dems Are Losing Tomorrow's Elections Today
America is outgrowing the Democratic Party.

more info


11/20/2024
Can a Fractured Democratic Party Learn the Lessons of 2024?
After a bruising campaign season and a humiliating defeat at the polls, this week saw Dems' internal conflicts spilling out into public view. Party insiders are now engaged in tit-for-tat Twitter battles that do nothing to offer the party a roadmap back to political contender status. Instead, they confirm normies' worst caricatures of Democratic dysfunction.

more info


11/20/2024
Pennsylvania Voters to Sen. Casey: 'It's Over, Bob'
Columnist David Marcus talks to voters in Bucks County and finds Democrats and Republicans agree that Sen. Bob Casey's refusal to concede is a bad look.

more info


11/20/2024
NC Republicans' Shameless New Power Grab
North Carolina voters spoke loud and clear two weeks ago when they elected Democrats to some of the most prominent statewide offices.

more info


11/20/2024
Trump Can and Should Fire Jerome Powell
Legacy media have been obsessing over whether President-elect Donald Trump can remove Jerome Powell, chairman of the Federal Reserve (the Fed). Jerome Powell recently came out and stated he would serve out his term - which ends in 2026. Further, Chairman Powell claims any attempt by President Trump to remove him is not "permitted under the law." Unfortunately for Chairman Powell, President-elect Trump can remove him - and he should - to make the federal bureaucracy respond to democratic pressures once again.

more info


11/20/2024
SecDef Austin: Women in Military Make U.S. Stronger
Austin in an exclusive interview with NBC News called women in the military a strong asset. Trump's choice for Secretary of Defense has cast doubt on women in combat roles.

more info


11/20/2024
Drone, Missile Defense Top Priorities for Next Defense Secretary
Pete Hegseth faces critical challenges in addressing U.S. vulnerabilities to advanced missile and drone threats as global tensions rise.

more info



Custom Search

More Politics Articles:

Related Articles

Get Ready for an American Energy Comeback


Judging from the headlines, America's energy sector could collapse at any moment. Scattered amidst coronavirus coverage are reports of plummeting energy stocks and commodities traders paying people to take barrels of oil off their hands.

Trump Administration Should Reject Foreign Prescription Drug Price Controls


In responding to the coronavirus pandemic, President Trump has rightly focused on the tremendous innovative capacity of American businesses -- first by waiving regulations that impose unnecessary burdens, next by providing incentives to get tough jobs such as vaccine development done as quickly as possible.

Clearing the Air on the EPA's Coronavirus Response


The Environmental Protection Agency (EPA) agency recently issued a memo waiving certain compliance requirements for energy firms in light of the COVID-19 outbreak. A group of House Democrats falsely claimed the EPA's memo gives oil and gas companies an "open license to pollute." To address lawmakers' concerns, the EPA has tapped an internal watchdog to review the policy. But no matter how hard they look, the investigators won't find anything close to what Democrats have suggested.

If Trump is Not Reelected, America Will Be Hurting


Most every American has an opinion about the upcoming election. However, there are several realities we must face.

For Workers' Sake, Keep the Pressure on America's Trading Partners


In his marathon testimony before Congress earlier this summer, United States Trade Representative Robert Lighthizer detailed the trade-policy achievements of President Trump's first term. It's a list that should make the administration proud.

Superbugs will Kill Millions — Unless Congress Acts


We're in the midst of the worst health crisis of the 21st century -- and it's not COVID.

Why Do We Take to the Streets?


We Americans are quick to take our disagreements to the streets. In 2020, we have claimed many causes to do so. Millions came out to protest police violence and “resist” fascism. Others “rallied” against COVID-19 lockdowns and voter fraud. We may amass crowds to evoke sympathy or provoke debate. But demonstrations aggravate and intimidate, often drawing counter protesters if not ending in violence. And even when gatherings generate debate, we are tempted to settle them by who had the larger crowd size rather than the merits of the case.

Biden Administration Must Commit to a National Pandemic Preparedness Strategy


COVID-19 has killed more than 350,000 Americans. And with case counts and hospitalizations soaring, many more deaths are sadly in store.

The FDA Can Help Patients With Rare Diseases


When I was just 18 years old, I was diagnosed with hypoparathyroidism, a rare disease that causes seizures, extreme fatigue and other life-altering complications.

A Simple Fix for Biden to Help to Make Drugs More Affordable


Americans have problems affording many drugs at pharmacies and doctors' offices. About half of those who are sick have trouble paying for their medications, according to a recent poll from the Kaiser Family Foundation.

America is Ready For a Resurrection


The followers of Jesus believed in his resurrection because they saw him alive after he was dead. They had a powerful testimony of firsthand evidence seen with their own eyes.

Small Changes to 340B Can Make a Big Difference for Struggling Patients


The Covid-19 pandemic has made the issue of healthcare access more urgent than ever. Yet, at a time of deep divisions in Washington, chances for major reform are slim.

The Need for Reconciliation is a Sign of a Bad Bill


"Budget Reconciliation" may be the most popular phrase on Capitol Hill right now. This special legislative process allows certain bills to be passed in the Senate with a simple majority so long as they impact the budget.

America was Prepared to Fight Covid-19 Thanks to Intellectual Property Rights


When Covid-19 came ashore, glaring gaps in the government's pandemic preparedness became painfully obvious. Everything from inadequate stockpiles of personal protective equipment to confusing and uncoordinated guidance regarding closures hampered our early response.

Democrats Chose the Worst Time to Revive Medicare for All


Medicare for All just won't die. More than 100 House Democrats have signed onto new legislation that would outlaw all private insurance and put all Americans on a federally-run insurance plan within two years.